Pfizer succeeds in Inlyta NICE appeal | PharmaBoardroom
written on 04.03.2014
Tags:
,

Pfizer succeeds in Inlyta NICE appeal

TAGS: ,

NICE said: "Following the appeal process, NICE issued an updated scope and matrix to include sunitinib and pazopanib as comparators in addition to best supportive care for the post-cytokine sub-group, and the manufacturer of axitinib submitted more…

Latest Report